|List |< first << previous [record 92 of 511] next >> last >||
|Mutation Type||splice donor site (6 bp from exon)|
|Coordinate||43,999,935 bp (GRCm38)|
|Base Change||T ⇒ G (forward strand)|
|Gene Name||serine peptidase inhibitor, Kazal type 5|
|Chromosomal Location||43,963,235-44,022,501 bp (+)|
|MGI Phenotype||Homozygous mutant mice display neonatal lethality, exfoliative erythroderma, and severe dehydration.|
|Limits of the Critical Region||15408000 - 46803000 bp|
|Amino Acid Change|
|Institutional Source||Beutler Lab|
Ensembl: ENSMUSP00000066214 (fasta)
|Gene Model||not available|
|Phenotypic Category||immune system, skin/coat/nails|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Live Mice, Sperm|
|Last Updated||2016-05-13 3:09 PM by Stephen Lyon|
|Record Created||2011-05-10 8:11 PM by Wataru Tomisato|
Crusty2 is a visible phenotype identified in F2 mice (Figure 1). Although the phenotype resembles crusty, crusty2 is not caused by a mutation in Foxp3. Both the crusty and crusty2 lines exhibit hard, flaky/scaly skin on their ears and tails (Figure 2). There is also the appearance of open wounds and scar tissue with a concomitant loss of hair on the face. Viability in the crusty2 mice is low; few survive past weaning.
Neutrophil content was assayed using fluorescence activated cell sorting (FACS) with splenocytes and lymph node cells stained with antibodies agains CD11b, Ly6G, and F4/80 (CD11b+Ly6G+F480- cells were recognized as neutrophils). FACS analysis revealed that the crusty2 mice had 3-30 times more neutrophils in their spleens and lymph nodes than WT (Table 1). However, animals with transplanted bone marrow had no difference in the amount of neutrophils in animals transplanted with wild-type (WT) or crusty2 bone marrow cells (Table 2). Furthermore, neither the crusty2 nor WT transplanted cells led to skin lesions.
|Nature of Mutation|
The crusty2 mutation was mapped using bulk segregation analysis (BSA) of F2 backcross offspring using C57BL/10J as the mapping strain (8 mutant and 23 normal). The mutation showed strongest linkage with marker B10SNPSG0180 at position 35366160 bp on Chromosome 18 (synthetic LOD = 4.0). Whole genome SOLiD sequencing of a homozygous crusty2 mouse and validation by capillary sequencing identified a T to G transition at bp 44159589 (6 bp after exon 17, within the donor splice site consensus sequence), 8.8 Mb from the marker of peak linkage, on chromosome 18 in the Genbank genomic region NC_000084, in Spink5. A secondary, incidental mutation was also found in Tcerg1 (a factor associated with transcriptional elongation and pre-mRNA splicing; data not shown).
<--EXON 17 INTRON 17 EXON 18-->
1669 ...ATGTGTTGGGCCTTCTT GTGAGTATA... CCAGCAAGAAGCCAA...
532 ...-M--C--W--A--F--F --Q--Q--E--A--K...
The mutated nucleotide is indicated in red lettering, the donor splice site consensus sequence is in blue. cDNA sequencing is underway to determine the changes to the Spink5 mRNA that occur upon the crusty2 mutation.
Computational analysis of mouse skin found that the transcription of the Spink5 gene generates two Spink5 transcripts (3394 bp and 4765 bp) with different 3’-untranslated regions (UTRs) that encode the same 1017 aa protein (1); Vega and Ensembl list a 4785 bp transcript as protein-coding. Mouse Spink5 is 60% identical and 71% homologous to human Spink5 with the exception that murine Spink5 has a 70 amino acid deletion of Kazal-type domain 6 as well as the linker between domains 6 and 7 (Figure 3) (1). Spink5 does not share significant homology to the other members of the Spink family (i.e. murine Spink3 or Spink4 as well as human SPINK1, SPINK2, or SPINK4) (1).
Spink5 is a member of a family of Kazal type serine protease inhibitors. In human tissues, the Spink family members are involved in the protection of epithelial and mucosal tissues against proteolytic degradation [reviewed in (2) and (3)]. The Spink5 transcript(s) encodes the lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein (Figures 4 & 5) (1;4). The LEKTI precursor protein has 15 potential inhibitory domains (D1-D15) (13 of which have a novel protein module of a Kazal-type-derived four-cysteine residue pattern) preceded by a signal peptide (1;4-8). These thirteen domains lack cysteines 3 and 6 of the canonical Kazal motif [C-(X)n-C-(X)7-C-(X)10-C-(X)2/3-C-(X)m-C], but they contain four conserved cysteines that form two intramolecular disulfide bonds (1;5;6). The other two domains, D2 and D15, contain the two additional cysteines of the typical Kazal-type proteinase inhibitor domains (5;9). The LETKI Kazal-type domain sequences form hairpin structures to create an inhibitory binding loop (7). The mouse hydrophobic Kazal-type domains are encoded by 128 bp exons; the spacers are encoded by exons of variable sizes (1) that contain many charged residues making them more susceptible to proteases (7;10).
The LEKTI precursor protein undergoes post-endoplasmic reticulum (ER) endoproteolytic cleavage (4;9;11). Several subtilisin-like proprotein convertase (SPC) consensus sequences are found within full-length LEKTI, indicating that LEKTI may be cleaved by SPCs to generate at least fourteen polypeptides (9). Furin, an SPC expressed in the epidermis, is thought to be essential for LEKTI peptide processing because LEKTI processing can be prevented by the application of a furin inhibitor (4;7;9;11-13). Although LEKTI can potentially generate fourteen polypeptides from the precursor, the detection of only three of these polypeptide fragments indicates that not all of these sites are utilized in vivo (9). The extent of the processing as well as the activity of the processed peptides is yet to be determined (12).
Full length recombinant LEKTI can inhibit trypsin, plasmin, subtilisin A, cathepsin G, and elastase (7;9;12). In addition, four of the 15 inhibitory domains can inhibit members of the kallikrein (KLK) family (i.e. KLK5, KLK7, and KLK14) (7;14). Domains D5 and D6 inhibit trypsin only, while a recombinant LEKTI that contains D6-D9 inhibits trypsin, KLK7, chymotrypsin, and subtilisin A, but not plasmin, cathepsin G, or elastase (8;15-17). The ability of LEKTI to inhibit several proteins reflects its diverse functions in several processes within the body including tissue homeostasis, inflammation, and antimicrobial defense (7;15;18).
PNGase treatment followed by Western blot analysis indicates that LEKTI is Asn (N)-linked glycosylated (1;9). Other Kazal inhibitor family members are N-glycosylated (e.g. ovomucoids, the major proteinase inhibitor from avian egg whites) (19), but the function of this posttranslational modification has not been elucidated. Another study showed evidence that LEKTI also undergoes O- (i.e. serine) linked glycosylation (7). It is proposed that O-glycosylation of LEKTI prevents furin from proteolytically cleaving LEKTI at the domain-linking regions (7). Prevention of furin activity would prevent the processing of the LEKTI precursor and promote the generation of multidomain and single domain fragments (7).
LEKTI is secreted into the intercellular space in the uppermost stratum granulosum (SG) layer of the skin (4;20-22). Northern blot and RT-PCR analyses have detected the expression of Spink5 in the thymus, vaginal epithelium, Bartholin gland, oral mucosa, tonsils, parathyroid gland, uterus, eye, and trachea (1;4;9;12;23). Although lower levels of Spink5 were detected in the lung, kidney, and prostate in human samples (4), Spink5 was not detected in the lung and kidney of the mouse (1). Dot blot analysis of mouse RNA revealed that the strongest Spink5 expression was in the prostate and the epididymis (23).
In situ hybridization and immunohistochemistry of mouse and human tissues detected LEKTI in the suprabasal layers of stratified epithelia, thymic Hassall bodies (i.e. terminally differentiated epithelial cells of the medulla), esophagus, the suprabasal cells of the stratified epithelia of tongue, the differentiated epithelia of the thymus medulla, and the keratinocytes of the granular layer of the epidermis where biochemical and morphological changes occur in terminal differentiation to lead to stratum corneum (SC) formation (1;7;9;14;21;24).
Several of the smaller peptides generated from processing of the full-length LEKTI protein have been isolated from human blood filtrate including domains one, five, and six (4;12); domain 8 has been isolated from human epidermal keratinocytes (12). In addition, other LEKTI proteolytic fragments have been found in human hair follicles (i.e. matrical cells of the bulb, the hair shaft cuticle, and the inner root sheath) (1;5;9).
The skin is an essential organ that protects the fragile internal tissues from injury. It is comprised of three major layers: the epidermis, dermis, and subcutaneous tissue. The epidermis is a physical barrier that limits the loss of fluid from the body as well as an adaptive immunological barrier composed of cellular and humoral components of the immune system and a chemical barrier that consists of antimicrobial peptides, lipids, acids, hydrolytic enzymes, and macrophages that defend the host from surrounding bacteria, fungi, and other potentially toxic materials (13;25;26). The epidermis has several structurally different layers: the SC (cornified layer and most superficial), stratum lucidum (clear/translucent), SG (granular), stratum spinosum (spinous), and the stratum basal (basal/germinal and most deep). Each layer indicates a different step in the basal cell differentiation process, terminating in cornification (i.e. the conversion of epithelium to stratified squamous) and desquamation (i.e. shedding) (13;27;28). The dermis contains the blood vessels and nerves of the skin and is the layer deep to the epidermal layer. It is comprised of collagen, elastic tissue, and reticular fibers. The subcutaneous tissue deep to the dermis is comprised of fat and connective tissue and is important for the regulation of skin and body temperature.
The primary cell type in the epidermis is keratinocytes that have proliferated from basal cells and differentiated to the terminally differentiated corneocytes that form the SC (13;15;26). The corneocytes are within a lipid-enriched extracellular matrix and are connected by corneodesmosomes (8;13;25). The SC layer regulates water release from the body, withstands mechanical forces, and prevents chemicals and microbes from penetrating the skin (25).
Proteases in the skin
Proteases are involved in epidermal differentiation as well as several other physiological functions including: T and B cell maturation, digestion, intercellular protein turnover, blood coagulation, the proteolytic activation of inactive precursors (e.g. enzymes and peptide hormones), and extracellular matrix remodeling [reviewed in (4;6;10)]. Proteases can be grouped in to one of several classes: serine (e.g. several allergens and digestive enzymes), threonine (e.g. the proteasome (18)), cysteine (e.g. calpains, cystatins, and cathepsins), aspartate (e.g. pepsins, renins, and cathepsins), metalloproteinase (e.g. matrix metalloproteases), or glutamate (this class is only found in fungi (29)) (4;10;18;26).
In order for desquamation to occur, the corneodesmosomes are degraded by proteases, often from the kallikrein (KLK) subfamily of trypsin-like serine proteases (e.g. KLK5 (i.e. SC tryptic enzyme (SCTE)) and KLK7 (i.e. SC chymotryptic enzyme (SCCE)); desquamation does not cause a barrier defect (6;13;15;26;30-32). The kallikreins are the largest family of trypsin- or chymotrypsin-like serine proteases [reviewed in (26)]. In addition to the cleavage of corneodesmosomes (33), kallikreins also facilitate the activation of protease-activated receptor (PAR)-2 (34), a receptor involved in signaling during epidermal inflammation (35) and the regulation of epidermal barrier function (36). In the first step of epidermal desquamation, pro-kallikreins are synthesized in the SG and are subsequently converted to their active forms (13). Next, to prevent the premature degradation of corneodesmosomes and premature desquamation in the granular layer and the SC, the active kallikreins form an inhibitory complex with LEKTI (7;13). The kallikreins that are not bound to LEKTI degrade corneodesmosomes and subsequent desquamation of the SC occurs [Figure 6; (13)].
Additional proteases in the skin include: matriptase, prostasin, caspase 14, cathepsin C, and cathepsin D (Table 3) [reviewed in (26)].
Table 3. Proteases in the skin.
Proteinase inhibitors are essential during cell differentiation, proliferation and migration (6). Pathological conditions (e.g. skin inflammation with a concomitant increase in shedding and a thickening of the skin) can occur when proteases are generated by viruses, bacteria, and parasites as well as when proteases are not regulated by proteinase inhibitors (Table 4) (4;26). Similar to the proteases, the function of the inhibitors is limited to a specific class of protease (19).
Table 4. Protease inhibitors of the skin [adapted from (26))
The most extensively studied class of inhibitors is the serine proteinase inhibitors. There are eleven families of serine protease inhibitors including SERPINs, Kunitz type, leuko-proteases, and Kazal type (71). The Kazal family is expressed in all vertebrates that have been examined to date, including human, bovine, ovine, and canine (19). In addition, they have also been extracted from nonvertebrates (i.e. leeches) (19). The Kazal family has a characteristic inhibitory domain that contains three conserved disulfide bonds and a reactive site loop (17;72). Each of the inhibitory domains can have specialized inhibitory functions (either individually or simultaneously) towards trypsin, chymotrypsin, elastase, and subtilisin (17;19;73).
LEKTI is proposed to be an anti-inflammatory factor (i.e. in the NF-κB-associated signaling pathway) that protects mucous epithelia (4;9;74). In addition, studies found that LEKTI has a role in the terminal differentiation of keratinocytes (by regulating the expression of keratin 10 and keratin 14 (markers of epidermal differentiation) and/or regulating profilaggrin processing (profilaggrin is an essential protein for skin development and barrier function; filaggrin is an intermediate filament that aids the packing of keratin filaments) and/or desquamation (1;7;15;75). The diverse localization of LEKTI indicates that, along with its role in desquamation, LEKTI could be involved in antimicrobial protection (indicated by LEKTI expression in tongue, vagina, and esophagus epithelia), hair growth, morphogenesis and differentiation (indicated by LEKTI expression in the hair shaft) (9;24), and in thymocyte differentiation (indicated by LEKTI expression in the thymus) (1;9). The function of LEKTI in Hassall’s bodies is currently unknown, but its strong expression points to a role in the regulation of T cell maturation (1;9). The localization of LEKTI in the SC also indicates that it targets SCTE and SCCE during desquamation (9;24;76;77); LEKTI and SCTE/SCCE are also colocalized in the hair follicle (9;24). Another possible target of LEKTI is membrane-type serine protease I (MT-SP1), which would subsequently lead to the inhibition of keratinocyte differentiation through the activation of PAR-2 at the keratinocyte surface (9).
Extracellular and intracellular pH is essential for maintaining the activity of several proteases in the skin as well as their association with protease inhibitors (7;13). For example, KLK5 and KLK7 are active at the neutral pH (pH 7.5) that is observed at the SG-SC interface (7). Also, the interaction with LEKTI and KLKs in the epidermis is strong at a neutral pH (7;8;13). Upon contact with the acidic environment of the upper SC (pH 4.5), LEKTI dissociates from the kallikreins, leading to restriction of the activity of the kallikreins and subsequently, desquamation of the uppermost layers of the SC (13;14). Taken together, acidification appears to be essential for the detachment of superficial corneocytes during desquamation (7). LEKTI is also regulated (in cultured keratinocytes) by external calcium concentrations (9).
LEKTI and Disease
Genetic abnormalities in Spink5 can cause atopy (MIM #147050), asthma (MIM #600807), and atopic dermatitis [Figure 6; MIM # 605845; (78-83)]. A common polymorphism in Spink5 associated with all of these diseases is a glutamic acid to lysine mutation at residue 420 (10;84). Atopic dermatitis (AD; or eczema), a chronic inflammatory condition of the skin, affects ~10-15% of the population (84;85). Individuals that have eczema have xerosis, itch, and erythematous lesions with increased transepidermal water loss (14). Often, in patients that have eczema, there is a subsequent development of asthma and food allergies (14;85). Eczema and asthma are both examples of atopic diseases (i.e. caused by an allergy) characterized by elevated levels of IgE (85).
One of the most extensively studied pathological conditions associated with LEKTI is Netherton Syndrome (MIM #256500). Netherton Syndrome (NS) is a condition in which the skin is chronically inflamed and undergoes scaling and/or a continuous peeling (6). Several LEKTI mutations that cause NS have been identified including, but not limited to: a nonsense mutation (R790X), insertions (i.e. 238insG, 720insT, 2258insG, 2468insA), deletions (i.e. 153delT, 1086delAT) and splice-site mutations, all of which are predicted to form premature termination codons (6;9;12;53;74). NS is an autosomal recessive condition that is characterized by congenital ichthyosis (i.e. dry, thickened and flaky skin) with defective cornification and keratinization, recurrent and sometimes persistent bacterial infections, dehydration, electrolyte imbalance, hypothermia, recurrent infections of the skin or respiratory tract, increased neonatal lethality, abnormal secretion of lamellar bodies, SC detachment, hair defects (i.e. ‘bamboo hair’), elevated IgE levels, food allergies, and elevated proteolytic activity in the suprabasal epidermis (1;5;6;9;12;13;15;24;53). In individuals with a severe form of the disease, the dry scaling skin can evolve into a migratory scaling and erythematous plaques (6). Furthermore, abnormalities observed in the hair shaft can result in alopecia (6). In NS, there is abnormal maturation of T lymphocytes leading to a disruption in the regulation of Th2 response to allergens. This disruption in Th2 function leads to acute hypersensitivity and increased IgE levels.
In addition to the skin-related phenotypes listed above for NS, patients can also have enteropathy (loss of protein through the intestine), hypernatremia (i.e. elevated sodium levels in the serum), hypoalbuminemia (i.e. low levels of albumin in the serum), aminoaciduria (i.e. amino acids in the urine), and developmental delay (86). In a study that examined patients with NS caused by a mutation in Spink5, NK T cells were increased while unswitched (CD19+CD27+IgM+IgD+) and switched (CD19+CD27+IgM-IgD-) memory B cells were decreased; γδ-T cells and regulatory T cells (CD4+CD25+FOXP3+) were not significantly changed from healthy controls (86). In addition, lymphocyte proliferation to mitogens and antigens were normal and serum IgE levels were significantly elevated (86). Proinflammatory and anti-inflammatory cytokines were increased in the serum of the patients with NS (86). However, the chemokine (C-C motif) ligand 5 (CCL5), a chemokine that is regulated on activation and is expressed and secreted by T cells, was decreased (86). Primary and/or secondary antibody responses were decreased in patients with NS (86). The abnormal antibody responses to bacteriophage observed in the NS patients from this study suggests that abnormal T-cell or B-cell development and/or defective costimulatory signaling leads to reduced isotype switching and defective immunologic memory. Intravenous immunoglobin replacement therapy in the NS patients led to a decrease in inflammation and an increase in NK-cell cytotoxicity (86).
In SC collected from NS patients with LEKTI mutations, the hydrolytic activity was increased compared to controls, indicating that serine proteases were overactive (24). Similar to the findins from several mouse models (see “LEKTI Mouse Models”, below), it is speculated that the increase in protease activity leads to an increased degradation of desmoglein-1 (DSG1) (24). Furthermore, it was proposed that KLK5 and KLK7 are regulated by LEKTI-derived inhibitors and affect hair growth and morphogenesis (24). Upon the loss of LEKTI-mediated inhibition in patients with NS, it is speculated that a cycle of chronic allergen-induced inflammation is induced by the expression of tryptase (9). The serine protease tryptase can mediate several allergic and inflammatory conditions through PAR-2 activation.
LEKTI Mouse Models
Several groups have studies the functional role of LEKTI by using mouse models. Knockout of LEKTI found that although the skin in the homozygous embryos was not significantly different from wild-type animals at embryonic day (E) 15.5, by E17.5, there was focal detachment of granular cells and the SC began to peel off; skin-barrier formation was normal (5). Heterozygous animals were normal (5). The loss of cell-cell adhesion, detachment of the SC, and the loss of barrier function resulted in perinatal death within hours of birth due to dehydration (5). Examination of the SC found that there was increased proteolytic activity and a premature degradation of extracellular desmosomal components (5). In addition, transmission electron microscopy of skin from the knockout animals demonstrated abnormal cornification (5). Loss of LEKTI expression resulted in higher proteinase activity in the SC, upper spinous, and SG layers compared to the wild-type animal (5). It was proposed that that the premature degradation of desmosomal components (i.e. corneodesmosin (CDSN), a protein that stabilizes the desmosome) could be caused by the increase in proteinase activity and that SCCE and SCTE cooperate with LEKTI to regulate the stability of CDSN (5).
A second study characterizing a LEKTI knockout found that the mice had impaired keratinization, hair malformation, defects in the skin barrier and altered desquamation (15). Similar to the previous study, this knockout model also died within a few hours of birth due to a loss of SC adherence and epidermal fragility (15). This study found that abnormal desmosome cleavage occurred following degradation of DSG1, a target of KLK5 and KLK7 (15). Furthermore, this study found that profilaggrin processing was increased, revealing that LEKTI is an essential member of cornification (15). In the LEKTI knockout mice, there was an increase in CDSN as well as a proposed abnormal proteolytic processing of CDSN (15). Characterization of the hair follicle found that intracellular adhesion was disrupted in the inner root sheath (IRS) and the between the IRS and the hair shaft (15).
A third study generated a mouse model with targeted disruption of Spink5 (7). Similar to the other knockout studies, the Spink5-null mice had disrupted desquamation and impaired keratinization, hair malformation, and skin barrier defects (7). Similar to the findings of Descargues et al., there was abnormal desmosome cleavage due to the loss of DSG1 (7).
In another study, a mutant LEKTI (R820X) was generated and characterized (12). Similar to the LEKTI knockout models, the R820X LEKTI animals lost skin barrier function, resulting in dehydration and subsequent death within a few hours after birth (12). In this model, it was determined that there was an increased proteolytic processing of profilaggrin in the skin, leading to defects in SC adhesion and compromised epidermal barrier function (12).
Similar to Spink5 null mice, the crusty2 mice do not thrive. In the null mice, the loss of cell-cell adhesion, detachment of the SC, and the loss of barrier function resulted in perinatal death within hours of birth due to dehydration (5;15). In addition, the crusty2 phenotype seems to mimic human NS in that the skin of the crusty2 mice is chronically inflamed. As listed above, there are several phenotypic characteristics of NS including dehydration, increased neonatal lethality, persistant bacterial infections, and congenital ichthyosis. In addition, in studies on patients with NS, the levels of NK T cells as well as B cells were changed from healthy individuals (86). Aberrant NK-cell function in NS patients was proposed to be due to a deficiency in NK cell-epithelial cell interaction (86).
It is possible that the crusty2 mutation is leading to an inability of immune cells to associate with epithelial cells of the skin, leading to the observed skin phenotype. Cathelicidins are innate antimicrobial peptides that are enzymatically processed by kallikreins from a proform to a mature peptide (e.g. LL-37 in neutrophils) (38). Increase in the expression of cathelicidin (and the subsequent mature peptides) is induced by infection, inflammation, and differentiation by promoting leukocyte chemotaxis, angiogenesis, and the expression of extracellular matrix components (37;38). Cathelicidin peptides at the skin surface are processed by kallikreins and this processing is altered in the absence of LEKTI (which is probable in crusty2) (38). Changes in the active form of cathelcidin in the skin would make the crusty2 mice more susceptible to microbes. Also, it is probable that there is increased proteolytic activity in the SC of the crusty2 mice as well as a premature degradation of desmosomal components (i.e. CDSN and DSG-1) as a result of the uninhibited activity of KLK5 and KLK7.
|Primers||Primers cannot be located by automatic search.|
Crusty2 genotyping is performed by amplifying a region containing a mutation in Spink5 using PCR followed by sequencing of the amplified region to detect the nucleotide change. The following primers were used for PCR amplification of Spink5:
Primers for PCR amplification
CRUSTY2_Spink5_PCR_F: 5'- GCAGCACATCACAGTTTTCAAAGGGA -3'
CRUSTY2_Spink5_PCR_R: 5'- CCCAGAAAATACATCTGCCACTCTGTT -3'
Primers for Sequencing
CRUSTY2_Spink5_Seq_F: 5'- CATCACAGTTTTCAAAGGGAGTAAG -3'
1) 94° C 2:00
2) 94° C 0:30
3) 57° C 0:30
4) 72° C 1:00
5) repeat steps (2-4) 29x
6) 72° C 7:00
7) 4° C ∞
The following sequence of 601 nucleotides (from Genbank genomic region: of the linear genomic sequence NC_000084.5 of Spink5) is amplified:
36421 gcag cacatcacag
36481 ttttcaaagg gagtaaggtg ggtgagggaa gttttgtagt gtttagtgat ctgattctca
36541 aatccttctt catttgacag gagctctgtc gtaaatacca tacccagctc agaaatgggc
36601 cgctccgctg caccagaagg aataacccca ttgagggcct ggatgggaag atgtataaaa
36661 atgcctgctt catgtgttgg gccttcttgt gagtatagct gcagccatta ctgttaggtg
36721 ttaaatgtag gggtggctta ctccagaaca ctgatgatga agcctgtctt tctttgtgct
36781 gagtttgggg gcagggtata ttatcatcaa gccacacact gacagtactt tctactgctt
36841 cagtgttctg aaagatgttg aaattatcac catagtagca tcatgtgcga ataccagata
36901 tccccagagt tatgttaata actcagtttc atgactaaca caaaggtaga gtcattcaat
36961 gataacaagt tgaaatttgt caacactaac catttttcta gttgttttct gtggaaaaaa
37021 atataaatct tcattcatca aaacagagtg gcagatgtat tttctggg
PCR primer binding sites are underlined and sequencing primer binding sites are highlighted; the mutated T is highlighted in red.
1. Galliano, M. F., Roccasecca, R. M., Descargues, P., Micheloni, A., Levy, E., Zambruno, G., D'Alessio, M., and Hovnanian, A. (2005) Characterization and Expression Analysis of the Spink5 Gene, the Mouse Ortholog of the Defective Gene in Netherton Syndrome. Genomics. 85, 483-492.
2. Wapenaar, M. C., Monsuur, A. J., Poell, J., van 't Slot, R., Meijer, J. W., Meijer, G. A., Mulder, C. J., Mearin, M. L., and Wijmenga, C. (2007) The SPINK Gene Family and Celiac Disease Susceptibility. Immunogenetics. 59, 349-357.
3. Rawlings, N. D., Tolle, D. P., and Barrett, A. J. (2004) Evolutionary Families of Peptidase Inhibitors. Biochem. J.. 378, 705-716.
4. Magert, H. J., Standker, L., Kreutzmann, P., Zucht, H. D., Reinecke, M., Sommerhoff, C. P., Fritz, H., and Forssmann, W. G. (1999) LEKTI, a Novel 15-Domain Type of Human Serine Proteinase Inhibitor. J. Biol. Chem.. 274, 21499-21502.
5. Yang, T., Liang, D., Koch, P. J., Hohl, D., Kheradmand, F., and Overbeek, P. A. (2004) Epidermal Detachment, Desmosomal Dissociation, and Destabilization of Corneodesmosin in Spink5-/- Mice. Genes Dev.. 18, 2354-2358.
6. Sprecher, E., Chavanas, S., DiGiovanna, J. J., Amin, S., Nielsen, K., Prendiville, J. S., Silverman, R., Esterly, N. B., Spraker, M. K., Guelig, E., de Luna, M. L., Williams, M. L., Buehler, B., Siegfried, E. C., Van Maldergem, L., Pfendner, E., Bale, S. J., Uitto, J., Hovnanian, A., and Richard, G. (2001) The Spectrum of Pathogenic Mutations in SPINK5 in 19 Families with Netherton Syndrome: Implications for Mutation Detection and First Case of Prenatal Diagnosis. J. Invest. Dermatol.. 117, 179-187.
7. Deraison, C., Bonnart, C., Lopez, F., Besson, C., Robinson, R., Jayakumar, A., Wagberg, F., Brattsand, M., Hachem, J. P., Leonardsson, G., and Hovnanian, A. (2007) LEKTI Fragments Specifically Inhibit KLK5, KLK7, and KLK14 and Control Desquamation through a pH-Dependent Interaction. Mol. Biol. Cell. 18, 3607-3619.
8. Roelandt, T., Thys, B., Heughebaert, C., De Vroede, A., De Paepe, K., Roseeuw, D., Rombaut, B., and Hachem, J. P. (2009) LEKTI-1 in Sickness and in Health. Int. J. Cosmet. Sci.. 31, 247-254.
9. Bitoun, E., Micheloni, A., Lamant, L., Bonnart, C., Tartaglia-Polcini, A., Cobbold, C., Al Saati, T., Mariotti, F., Mazereeuw-Hautier, J., Boralevi, F., Hohl, D., Harper, J., Bodemer, C., D'Alessio, M., and Hovnanian, A. (2003) LEKTI Proteolytic Processing in Human Primary Keratinocytes, Tissue Distribution and Defective Expression in Netherton Syndrome. Hum. Mol. Genet.. 12, 2417-2430.
10. Walley, A. J., Chavanas, S., Moffatt, M. F., Esnouf, R. M., Ubhi, B., Lawrence, R., Wong, K., Abecasis, G. R., Jones, E. Y., Harper, J. I., Hovnanian, A., and Cookson, W. O. (2001) Gene Polymorphism in Netherton and Common Atopic Disease. Nat. Genet.. 29, 175-178.
11. Tartaglia-Polcini, A., Bonnart, C., Micheloni, A., Cianfarani, F., Andre, A., Zambruno, G., Hovnanian, A., and D'Alessio, M. (2006) SPINK5, the Defective Gene in Netherton Syndrome, Encodes Multiple LEKTI Isoforms Derived from Alternative Pre-mRNA Processing. J. Invest. Dermatol.. 126, 315-324.
12. Hewett, D. R., Simons, A. L., Mangan, N. E., Jolin, H. E., Green, S. M., Fallon, P. G., and McKenzie, A. N. (2005) Lethal, Neonatal Ichthyosis with Increased Proteolytic Processing of Filaggrin in a Mouse Model of Netherton Syndrome. Hum. Mol. Genet.. 14, 335-346.
13. Sales, K. U., Masedunskas, A., Bey, A. L., Rasmussen, A. L., Weigert, R., List, K., Szabo, R., Overbeek, P. A., and Bugge, T. H. (2010) Matriptase Initiates Activation of Epidermal Pro-Kallikrein and Disease Onset in a Mouse Model of Netherton Syndrome. Nat. Genet.. 42, 676-683.
14. Cork, M. J., Danby, S. G., Vasilopoulos, Y., Hadgraft, J., Lane, M. E., Moustafa, M., Guy, R. H., Macgowan, A. L., Tazi-Ahnini, R., and Ward, S. J. (2009) Epidermal Barrier Dysfunction in Atopic Dermatitis. J. Invest. Dermatol.. 129, 1892-1908.
15. Descargues, P., Deraison, C., Bonnart, C., Kreft, M., Kishibe, M., Ishida-Yamamoto, A., Elias, P., Barrandon, Y., Zambruno, G., Sonnenberg, A., and Hovnanian, A. (2005) Spink5-Deficient Mice Mimic Netherton Syndrome through Degradation of Desmoglein 1 by Epidermal Protease Hyperactivity. Nat. Genet.. 37, 56-65.
16. Jayakumar, A., Kang, Y., Mitsudo, K., Henderson, Y., Frederick, M. J., Wang, M., El-Naggar, A. K., Marx, U. C., Briggs, K., and Clayman, G. L. (2004) Expression of LEKTI Domains 6-9' in the Baculovirus Expression System: Recombinant LEKTI Domains 6-9' Inhibit Trypsin and Subtilisin A. Protein Expr. Purif.. 35, 93-101.
17. Schechter, N. M., Choi, E. J., Wang, Z. M., Hanakawa, Y., Stanley, J. R., Kang, Y., Clayman, G. L., and Jayakumar, A. (2005) Inhibition of Human Kallikreins 5 and 7 by the Serine Protease Inhibitor Lympho-Epithelial Kazal-Type Inhibitor (LEKTI). Biol. Chem.. 386, 1173-1184.
18. Baird, T. T.,Jr, Wright, W. D., and Craik, C. S. (2006) Conversion of Trypsin to a Functional Threonine Protease. Protein Sci.. 15, 1229-1238.
19. Laskowski, M.,Jr, and Kato, I. (1980) Protein Inhibitors of Proteinases. Annu. Rev. Biochem.. 49, 593-626.
20. Ishida-Yamamoto, A., Simon, M., Kishibe, M., Miyauchi, Y., Takahashi, H., Yoshida, S., O'Brien, T. J., Serre, G., and Iizuka, H. (2004) Epidermal Lamellar Granules Transport Different Cargoes as Distinct Aggregates. J. Invest. Dermatol.. 122, 1137-1144.
21. Ishida-Yamamoto, A., Deraison, C., Bonnart, C., Bitoun, E., Robinson, R., O'Brien, T. J., Wakamatsu, K., Ohtsubo, S., Takahashi, H., Hashimoto, Y., Dopping-Hepenstal, P. J., McGrath, J. A., Iizuka, H., Richard, G., and Hovnanian, A. (2005) LEKTI is Localized in Lamellar Granules, Separated from KLK5 and KLK7, and is Secreted in the Extracellular Spaces of the Superficial Stratum Granulosum. J. Invest. Dermatol.. 124, 360-366.
22. Sondell, B., Thornell, L. E., and Egelrud, T. (1995) Evidence that Stratum Corneum Chymotryptic Enzyme is Transported to the Stratum Corneum Extracellular Space Via Lamellar Bodies. J. Invest. Dermatol.. 104, 819-823.
23. Magert, H. J., Kreutzmann, P., Standker, L., Walden, M., Drogemuller, K., and Forssmann, W. G. (2002) LEKTI: A Multidomain Serine Proteinase Inhibitor with Pathophysiological Relevance. Int. J. Biochem. Cell Biol.. 34, 573-576.
24. Komatsu, N., Takata, M., Otsuki, N., Ohka, R., Amano, O., Takehara, K., and Saijoh, K. (2002) Elevated Stratum Corneum Hydrolytic Activity in Netherton Syndrome Suggests an Inhibitory Regulation of Desquamation by SPINK5-Derived Peptides. J. Invest. Dermatol.. 118, 436-443.
25. Proksch, E., Brandner, J. M., and Jensen, J. M. (2008) The Skin: An Indispensable Barrier. Exp. Dermatol.. 17, 1063-1072.
26. Meyer-Hoffert, U. (2009) Reddish, Scaly, and Itchy: How Proteases and their Inhibitors Contribute to Inflammatory Skin Diseases. Arch. Immunol. Ther. Exp. (Warsz). 57, 345-354.
28. Vaughan, F. L., and Bernstein, I. A. (1976) Molecular Aspects of Control in Epidermal Differentiation. Mol. Cell. Biochem.. 12, 171-179.
29. Sims, A. H., Dunn-Coleman, N. S., Robson, G. D., and Oliver, S. G. (2004) Glutamic Protease Distribution is Limited to Filamentous Fungi. FEMS Microbiol. Lett.. 239, 95-101.
30. Lundstrom, A., and Egelrud, T. (1990) Evidence that Cell Shedding from Plantar Stratum Corneum in Vitro Involves Endogenous Proteolysis of the Desmosomal Protein Desmoglein I. J. Invest. Dermatol.. 94, 216-220.
31. Ekholm, E., and Egelrud, T. (2000) Expression of Stratum Corneum Chymotryptic Enzyme in Relation to Other Markers of Epidermal Differentiation in a Skin Explant Model. Exp. Dermatol.. 9, 65-70.
32. Ekholm, I. E., Brattsand, M., and Egelrud, T. (2000) Stratum Corneum Tryptic Enzyme in Normal Epidermis: A Missing Link in the Desquamation Process? J. Invest. Dermatol.. 114, 56-63.
33. Egelrud, T. (2000) Desquamation in the Stratum Corneum. Acta Derm Venereol. Suppl. (Stockh). 208, 44-45.
34. Stefansson, K., Brattsand, M., Roosterman, D., Kempkes, C., Bocheva, G., Steinhoff, M., and Egelrud, T. (2008) Activation of Proteinase-Activated Receptor-2 by Human Kallikrein-Related Peptidases. J. Invest. Dermatol.. 128, 18-25.
35. Steinhoff, M., Buddenkotte, J., Shpacovitch, V., Rattenholl, A., Moormann, C., Vergnolle, N., Luger, T. A., and Hollenberg, M. D. (2005) Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response. Endocr. Rev.. 26, 1-43.
36. Hachem, J. P., Houben, E., Crumrine, D., Man, M. Q., Schurer, N., Roelandt, T., Choi, E. H., Uchida, Y., Brown, B. E., Feingold, K. R., and Elias, P. M. (2006) Serine Protease Signaling of Epidermal Permeability Barrier Homeostasis. J. Invest. Dermatol.. 126, 2074-2086.
37. Yamasaki, K., Di Nardo, A., Bardan, A., Murakami, M., Ohtake, T., Coda, A., Dorschner, R. A., Bonnart, C., Descargues, P., Hovnanian, A., Morhenn, V. B., and Gallo, R. L. (2007) Increased Serine Protease Activity and Cathelicidin Promotes Skin Inflammation in Rosacea. Nat. Med.. 13, 975-980.
38. Yamasaki, K., Schauber, J., Coda, A., Lin, H., Dorschner, R. A., Schechter, N. M., Bonnart, C., Descargues, P., Hovnanian, A., and Gallo, R. L. (2006) Kallikrein-Mediated Proteolysis Regulates the Antimicrobial Effects of Cathelicidins in Skin. FASEB J.. 20, 2068-2080.
39. Hansson, L., Backman, A., Ny, A., Edlund, M., Ekholm, E., Ekstrand Hammarstrom, B., Tornell, J., Wallbrandt, P., Wennbo, H., and Egelrud, T. (2002) Epidermal Overexpression of Stratum Corneum Chymotryptic Enzyme in Mice: A Model for Chronic Itchy Dermatitis. J. Invest. Dermatol.. 118, 444-449.
40. Komatsu, N., Takata, M., Otsuki, N., Toyama, T., Ohka, R., Takehara, K., and Saijoh, K. (2003) Expression and Localization of Tissue Kallikrein mRNAs in Human Epidermis and Appendages. J. Invest. Dermatol.. 121, 542-549.
41. Komatsu, N., Suga, Y., Saijoh, K., Liu, A. C., Khan, S., Mizuno, Y., Ikeda, S., Wu, H. K., Jayakumar, A., Clayman, G. L., Shirasaki, F., Takehara, K., and Diamandis, E. P. (2006) Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-Desquamation of Corneocytes. J. Invest. Dermatol.. 126, 2338-2342.
42. Komatsu, N., Saijoh, K., Toyama, T., Ohka, R., Otsuki, N., Hussack, G., Takehara, K., and Diamandis, E. P. (2005) Multiple Tissue Kallikrein mRNA and Protein Expression in Normal Skin and Skin Diseases. Br. J. Dermatol.. 153, 274-281.
43. Alef, T., Torres, S., Hausser, I., Metze, D., Tursen, U., Lestringant, G. G., and Hennies, H. C. (2009) Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 is Associated with Impaired Profilaggrin Processing. J. Invest. Dermatol.. 129, 862-869.
44. Bugge, T. H., List, K., and Szabo, R. (2007) Matriptase-Dependent Cell Surface Proteolysis in Epithelial Development and Pathogenesis. Front. Biosci.. 12, 5060-5070.
45. Netzel-Arnett, S., Currie, B. M., Szabo, R., Lin, C. Y., Chen, L. M., Chai, K. X., Antalis, T. M., Bugge, T. H., and List, K. (2006) Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation. J. Biol. Chem.. 281, 32941-32945.
46. Demerjian, M., Hachem, J. P., Tschachler, E., Denecker, G., Declercq, W., Vandenabeele, P., Mauro, T., Hupe, M., Crumrine, D., Roelandt, T., Houben, E., Elias, P. M., and Feingold, K. R. (2008) Acute Modulations in Permeability Barrier Function Regulate Epidermal Cornification: Role of Caspase-14 and the Protease-Activated Receptor Type 2. Am. J. Pathol.. 172, 86-97.
47. Denecker, G., Hoste, E., Gilbert, B., Hochepied, T., Ovaere, P., Lippens, S., Van den Broecke, C., Van Damme, P., D'Herde, K., Hachem, J. P., Borgonie, G., Presland, R. B., Schoonjans, L., Libert, C., Vandekerckhove, J., Gevaert, K., Vandenabeele, P., and Declercq, W. (2007) Caspase-14 Protects Against Epidermal UVB Photodamage and Water Loss. Nat. Cell Biol.. 9, 666-674.
48. Hart, T. C., Hart, P. S., Bowden, D. W., Michalec, M. D., Callison, S. A., Walker, S. J., Zhang, Y., and Firatli, E. (1999) Mutations of the Cathepsin C Gene are Responsible for Papillon-Lefevre Syndrome. J. Med. Genet.. 36, 881-887.
49. Hart, T. C., Hart, P. S., Michalec, M. D., Zhang, Y., Firatli, E., Van Dyke, T. E., Stabholz, A., Zlotogorski, A., Shapira, L., and Soskolne, W. A. (2000) Haim-Munk Syndrome and Papillon-Lefevre Syndrome are Allelic Mutations in Cathepsin C. J. Med. Genet.. 37, 88-94.
50. Pham, C. T., and Ley, T. J. (1999) Dipeptidyl Peptidase I is Required for the Processing and Activation of Granzymes A and B in Vivo. Proc. Natl. Acad. Sci. U. S. A.. 96, 8627-8632.
51. Horikoshi, T., Arany, I., Rajaraman, S., Chen, S. H., Brysk, H., Lei, G., Tyring, S. K., and Brysk, M. M. (1998) Isoforms of Cathepsin D and Human Epidermal Differentiation. Biochimie. 80, 605-612.
52. Horikoshi, T., Igarashi, S., Uchiwa, H., Brysk, H., and Brysk, M. M. (1999) Role of Endogenous Cathepsin D-Like and Chymotrypsin-Like Proteolysis in Human Epidermal Desquamation. Br. J. Dermatol.. 141, 453-459.
53. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A. D., Bonafe, J. L., Wilkinson, J., Taieb, A., Barrandon, Y., Harper, J. I., de Prost, Y., and Hovnanian, A. (2000) Mutations in SPINK5, Encoding a Serine Protease Inhibitor, Cause Netherton Syndrome. Nat. Genet.. 25, 141-142.
54. Mitsudo, K., Jayakumar, A., Henderson, Y., Frederick, M. J., Kang, Y., Wang, M., El-Naggar, A. K., and Clayman, G. L. (2003) Inhibition of Serine Proteinases Plasmin, Trypsin, Subtilisin A, Cathepsin G, and Elastase by LEKTI: A Kinetic Analysis. Biochemistry. 42, 3874-3881.
55. Brattsand, M., Stefansson, K., Hubiche, T., Nilsson, S. K., and Egelrud, T. (2009) SPINK9: A Selective, Skin-Specific Kazal-Type Serine Protease Inhibitor. J. Invest. Dermatol.. 129, 1656-1665.
56. Meyer-Hoffert, U., Wu, Z., and Schroder, J. M. (2009) Identification of Lympho-Epithelial Kazal-Type Inhibitor 2 in Human Skin as a Kallikrein-Related Peptidase 5-Specific Protease Inhibitor. PLoS One. 4, e4372.
57. Wiedow, O., Luademann, J., and Utecht, B. (1991) Elafin is a Potent Inhibitor of Proteinase 3. Biochem. Biophys. Res. Commun.. 174, 6-10.
58. Wiedow, O., Schroder, J. M., Gregory, H., Young, J. A., and Christophers, E. (1990) Elafin: An Elastase-Specific Inhibitor of Human Skin. Purification, Characterization, and Complete Amino Acid Sequence. J. Biol. Chem.. 265, 14791-14795.
59. Walz, M., Kellermann, S., Bylaite, M., Andree, B., Ruther, U., Paus, R., Kloepper, J. E., Reifenberger, J., and Ruzicka, T. (2007) Expression of the Human Cathepsin L Inhibitor Hurpin in Mice: Skin Alterations and Increased Carcinogenesis. Exp. Dermatol.. 16, 715-723.
60. Silverman, G. A., Bartuski, A. J., Cataltepe, S., Gornstein, E. R., Kamachi, Y., Schick, C., and Uemura, Y. (1998) SCCA1 and SCCA2 are Proteinase Inhibitors that Map to the Serpin Cluster at 18q21.3. Tumour Biol.. 19, 480-487.
61. Komiyama, T., Gron, H., Pemberton, P. A., and Salvesen, G. S. (1996) Interaction of Subtilisins with Serpins. Protein Sci.. 5, 874-882.
62. Munch, J., Standker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pohlmann, S., Chaipan, C., Biet, T., Peters, T., Meyer, B., Wilhelm, D., Lu, H., Jing, W., Jiang, S., Forssmann, W. G., and Kirchhoff, F. (2007) Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide. Cell. 129, 263-275.
63. Dahlen, J. R., Foster, D. C., and Kisiel, W. (1997) Human Proteinase Inhibitor 9 (PI9) is a Potent Inhibitor of Subtilisin A. Biochem. Biophys. Res. Commun.. 238, 329-333.
64. Bjorck, L. (1990) Proteinase Inhibition, Immunoglobulin-Binding Proteins and a Novel Antimicrobial Principle. Mol. Microbiol.. 4, 1439-1442.
65. Bobek, L. A., and Levine, M. J. (1992) Cystatins--Inhibitors of Cysteine Proteinases. Crit. Rev. Oral Biol. Med.. 3, 307-332.
66. Turk, V., and Bode, W. (1991) The Cystatins: Protein Inhibitors of Cysteine Proteinases. FEBS Lett.. 285, 213-219.
67. Cheng, T., Hitomi, K., van Vlijmen-Willems, I. M., de Jongh, G. J., Yamamoto, K., Nishi, K., Watts, C., Reinheckel, T., Schalkwijk, J., and Zeeuwen, P. L. (2006) Cystatin M/E is a High Affinity Inhibitor of Cathepsin V and Cathepsin L by a Reactive Site that is Distinct from the Legumain-Binding Site. A Novel Clue for the Role of Cystatin M/E in Epidermal Cornification. J. Biol. Chem.. 281, 15893-15899.
68. Zeeuwen, P. L., van Vlijmen-Willems, I. M., Olthuis, D., Johansen, H. T., Hitomi, K., Hara-Nishimura, I., Powers, J. C., James, K. E., op den Camp, H. J., Lemmens, R., and Schalkwijk, J. (2004) Evidence that Unrestricted Legumain Activity is Involved in Disturbed Epidermal Cornification in Cystatin M/E Deficient Mice. Hum. Mol. Genet.. 13, 1069-1079.
69. Zeeuwen, P. L., van Vlijmen-Willems, I. M., Hendriks, W., Merkx, G. F., and Schalkwijk, J. (2002) A Null Mutation in the Cystatin M/E Gene of Ichq Mice Causes Juvenile Lethality and Defects in Epidermal Cornification. Hum. Mol. Genet.. 11, 2867-2875.
70. Zeeuwen, P. L., van Vlijmen-Willems, I. M., Egami, H., and Schalkwijk, J. (2002) Cystatin M / E Expression in Inflammatory and Neoplastic Skin Disorders. Br. J. Dermatol.. 147, 87-94.
71. Bode, W., and Huber, R. (1992) Natural Protein Proteinase Inhibitors and their Interaction with Proteinases. Eur. J. Biochem.. 204, 433-451.
72. Roberts, R. M., Mathialagan, N., Duffy, J. Y., and Smith, G. W. (1995) Regulation and Regulatory Role of Proteinase Inhibitors. Crit. Rev. Eukaryot. Gene Expr.. 5, 385-436.
73. Saxena, I., and Tayyab, S. (1997) Protein Proteinase Inhibitors from Avian Egg Whites. Cell Mol. Life Sci.. 53, 13-23.
74. Mizuno, Y., Suga, Y., Muramatsu, S., Hasegawa, T., Shimizu, T., and Ogawa, H. (2005) A Japanese Infant with Localized Ichthyosis Linearis Circumflexa on the Palms and Soles Harbouring a Compound Heterozygous Mutation in the SPINK5 Gene. Br. J. Dermatol.. 153, 661-663.
75. Kuechle, M. K., Presland, R. B., Lewis, S. P., Fleckman, P., and Dale, B. A. (2000) Inducible Expression of Filaggrin Increases Keratinocyte Susceptibility to Apoptotic Cell Death. Cell Death Differ.. 7, 566-573.
76. Brattsand, M., and Egelrud, T. (1999) Purification, Molecular Cloning, and Expression of a Human Stratum Corneum Trypsin-Like Serine Protease with Possible Function in Desquamation. J. Biol. Chem.. 274, 30033-30040.
77. Hansson, L., Stromqvist, M., Backman, A., Wallbrandt, P., Carlstein, A., and Egelrud, T. (1994) Cloning, Expression, and Characterization of Stratum Corneum Chymotryptic Enzyme. A Skin-Specific Human Serine Proteinase. J. Biol. Chem.. 269, 19420-19426.
78. Nishio, Y., Noguchi, E., Shibasaki, M., Kamioka, M., Ichikawa, E., Ichikawa, K., Umebayashi, Y., Otsuka, F., and Arinami, T. (2003) Association between Polymorphisms in the SPINK5 Gene and Atopic Dermatitis in the Japanese. Genes Immun.. 4, 515-517.
79. Castro-Giner, F., de Cid, R., Gonzalez, J. R., Jarvis, D., Heinrich, J., Janson, C., Omenaas, E. R., Matheson, M. C., Pin, I., Anto, J. M., Wjst, M., Estivill, X., and Kogevinas, M. (2010) Positionally Cloned Genes and Age-Specific Effects in Asthma and Atopy: An International Population-Based Cohort Study (ECRHS). Thorax. 65, 124-131.
80. Liu, Q., Xia, Y., Zhang, W., Li, J., Wang, P., Li, H., Wei, C., and Gong, Y. (2009) A Functional Polymorphism in the SPINK5 Gene is Associated with Asthma in a Chinese Han Population. BMC Med. Genet.. 10, 59.
81. Parate, P. N., Wang de, Y., and Chew, F. T. (2010) Linkage Disequilibrium Pattern in Asthma Candidate Genes from 5q31-q33 in the Singapore Chinese Population. Ann. Hum. Genet.. 74, 137-145.
82. Namkung, J. H., Lee, J. E., Kim, E., Byun, J. Y., Kim, S., Shin, E. S., Cho, E. Y., and Yang, J. M. (2010) Hint for Association of Single Nucleotide Polymorphisms and Haplotype in SPINK5 Gene with Atopic Dermatitis in Koreans. Exp. Dermatol.. 19, 1048-1053.
83. Zhao, L. P., Di, Z., Zhang, L., Wang, L., Ma, L., Lv, Y., Hong, Y., Wei, H., Chen, H. D., and Gao, X. H. (2011) Association of SPINK5 Gene Polymorphisms with Atopic Dermatitis in Northeast China. J. Eur. Acad. Dermatol. Venereol.. .
84. Kato, A., Fukai, K., Oiso, N., Hosomi, N., Murakami, T., and Ishii, M. (2003) Association of SPINK5 Gene Polymorphisms with Atopic Dermatitis in the Japanese Population. Br. J. Dermatol.. 148, 665-669.
85. Norgett, E. E., and Kelsell, D. P. (2002) SPINK5: Both Rare and Common Skin Disease. Trends Mol. Med.. 8, 7.
86. Renner, E. D., Hartl, D., Rylaarsdam, S., Young, M. L., Monaco-Shawver, L., Kleiner, G., Markert, M. L., Stiehm, E. R., Belohradsky, B. H., Upton, M. P., Torgerson, T. R., Orange, J. S., and Ochs, H. D. (2009) Comel-Netherton Syndrome Defined as Primary Immunodeficiency. J. Allergy Clin. Immunol.. 124, 536-543.
|Science Writers||Anne Murray|
|Illustrators||Diantha La Vine, Victoria Webster|
|Authors||Wataru Tomisato, Owen M. Siggs, Bruce Beutler|
|List |< first << previous [record 92 of 511] next >> last >||